Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Tuesday, July 7, 2026

Snapshot: Jul 7, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Tue, Jul 7, 2026 Divergent High

Market divergence as mega-cap tech stumbles while small biotech names surge on takeovers and clinical wins, with VIX cooling despite extreme single-stock dispersion.

55% Tech and mega-cap weakness dragged the Nasdaq 100 down 2.0% and midcaps off 1.5%, even as the S&P 500 managed a modest 0.85% gain—a classic value-rotation day where large-cap breadth masked the damage underneath, with Financial Services bearing the worst losses (44% of losers) while healthcare drove 36% of gainers.
30% Extreme dispersion with 50 stocks surging over 24% on average, led by biotech and pharma names like CRNX (+99% on Vertex's $10B takeover of Crinetics), TVRD (+54% on Phase 1 data), SKIN (+47% on FDA clearance), and AGIO (+18% on Priority Review for sickle cell therapy), alongside mystery gainers like CLRO and SKYQ that rallied 98% and 42% with insufficient news catalysts.
15% VIX dropped 8.6% to 16.13 as fear eased despite the market's internal carnage, and JEM extended a 5-day losers streak while five debut gainers (CRNX, FHTX, AGIO, IVA, IMMX) signaled a major wave of biotech and healthcare volatility reigniting after long absences.

Healthcare drove 36% of gainers JEM on a 5-day losers streak 5 names returned after long absences JEM · 5-day losers streak CRNX — first appearance FHTX — first appearance

Market Regime

Tue, Jul 7, 2026 Neutral conf: low macro · prototype

+22

Tailwind −100 … +100 · + tailwind / − headwind

VIX16.1 Drawdown-1.4% Held1d · nascent SinceJul 7

Top drivers: Small-cap leadership ▲ S&P drawdown (60d) ▲ S&P 20d return ▲

processId: history-market-regime

Market Indexes

Tue, Jul 7, 2026 13

S&P 500

7,503.85

+63.42

+0.85%

Dow Jones

52,925.15

+742.41

+1.42%

NASDAQ Composite

25,818.69

−1.45

-0.01%

NASDAQ 100

29,173.02

−601.73

-2.02%

DJ US Total Market

74,429.02

+454.03

+0.61%

Russell 1000

4,092.01

+30.18

+0.74%

S&P MidCap 400

3,771.77

−56.31

-1.47%

Russell 2000

2,982.49

−27.93

-0.93%

Russell 2500

1,265.25

−13.59

-1.06%

Russell 3000

4,274.94

+28.47

+0.67%

Nasdaq Financial-100

7,466.60

+355.30

+5.00%

NIFTY 50

24,398.70

+392.85

+1.64%

VIX

16.13

−1.52

-8.61%

Biggest Gainers

Tue, Jul 7, 2026 50

CRNX

Crinetics Pharmaceuticals, Inc.Healthcare

$83.53+$41.50

+98.7%

CLRO

ClearOne, Inc.Technology

$13.84+$6.84

+97.7%

NASDAQ · Mkt cap $13 M

ClearOne surged nearly 98 percent with no news headlines in the last 48 hours, suggesting the move was driven by technical factors, a delayed announcement not yet indexed in RSS feeds, or market speculation rather than a publicly announced catalyst.

No recent news headlines are available to explain this dramatic 97.71 percent gain, which places CLRO among the top two gainers of the day. In situations where a stock moves this sharply without corresponding news coverage, the cause is typically one of several categories. First, the move could reflect a delayed announcement that hasn't yet propagated to major financial RSS feeds but has reached traders through other channels. Second, short covering or a technical squeeze could drive rapid repricing if the stock was heavily shorted or held key technical support levels. Third, a rumor or social media catalyst unrelated to formal news wires might have sparked retail interest. Without access to the specific price action details, intraday volume patterns, or short interest data, these remain reasonable hypotheses rather than established causes. The absence of identifiable corporate news within 48 hours makes it difficult to pinpoint a definitive trigger.

TVRD

Tvardi Therapeutics, Inc.Healthcare

$3.10+$1.09

+54.2%

NASDAQ · Mkt cap $25 M

Tvardi Therapeutics announced positive Phase 1 data for TTI-109 showing improved tolerability and evidence of target engagement against STAT3, likely driving the 54% gain as a clinical-stage biotech milestone.

On July 7, 2026, Tvardi released Phase 1 results for TTI-109 demonstrating that the prodrug achieved TTI-101-equivalent drug exposure while exhibiting improved tolerability compared to the parent compound. The data also showed meaningful reductions in disease-relevant STAT3-driven immune populations including Th17, T follicular helper cells, and B cells, confirming target engagement. For a clinical-stage therapeutic company, positive Phase 1 proof-of-concept data—especially evidence of both safety improvement and biological mechanism validation—typically triggers significant positive re-rating. The stock's position as the third biggest gainer on the day suggests the market viewed this as material validation of the TTI-109 development strategy. No competing news or offsetting developments are evident in the headlines provided.

SKIN

The Beauty Health CompanyHealthcare

$1.11+$0.36

+47.0%

NASDAQ · Mkt cap $98 M

The Beauty Health Company surged 47% on FDA clearance for its SkinStylus device to treat periorbital wrinkles across all skin types, expanding the device's approved indications and competitive positioning in the microneedling market.

The headline documents a specific regulatory win: the SkinStylus received FDA clearance for a new cosmetic indication (periorbital wrinkles for all skin types). The news also emphasizes that the device now holds multiple cleared indications including facial acne scars, positioning it as the only microneedling device with this breadth of labeled claims. For a micro-cap medical device company trading near $1.11, a newly cleared indication that expands addressable market and competitive moat is a material catalyst. The stock was likely depressed prior to this announcement, making the 47% move consistent with relief buying and genuine therapeutic expansion news. No countervailing headlines or negative developments are evident in the provided data.

AKTX

Akari Therapeutics, PlcHealthcare

$15.48+$4.58

+42.0%

NASDAQ · Mkt cap $14 M

Akari Therapeutics surged 42% on July 7th following the appointment of Patricia LoRusso, former AACR president and respected oncology drug development leader, to the company's Scientific Advisory Board, signaling strategic progress in its novel ADC RNA-splicing program.

The headline from July 7th at 12:55 UTC announces that Akari has recruited Patricia LoRusso, D.O., a globally recognized figure in early-phase oncology clinical development, to its Scientific Advisory Board. This comes as the company advances a novel antibody-drug conjugate payload designed to modulate RNA splicing into future Phase trials. In small-cap biotech and therapeutics companies, the addition of high-profile scientific advisors—especially former presidents of major organizations like the American Association for Cancer Research—typically signals credibility enhancement and can boost investor confidence in the company's pipeline and execution strategy. The timing of this announcement coincides with the stock's 42% jump on the same day, making this the most plausible near-term catalyst. A general market note about ADRs being lower appears unrelated to this stock-specific positive development.

SKYQ

Sky Quarry Inc.Energy

$3.00+$0.88

+41.5%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours for Sky Quarry Inc., so the 41.51% gain on July 7, 2026 likely reflects a delayed market reaction to an older announcement, technical/algorithmic trading, or undetected private information.

The absence of any recent news in the Yahoo Finance RSS feed over the last 48 hours is noteworthy given the stock's sharp 41.51% single-day gain and its ranking as the sixth-largest gainer on NASDAQ. This disconnect suggests several possibilities. First, the catalyst may predate the 48-hour window and is only now being processed by the market or retail trading platforms. Second, the move could reflect technical factors such as short covering, algorithmic trading rebalancing, or breakout buying following a period of consolidation. Third, for micro-cap or less-liquid stocks, moves of this magnitude can occasionally occur on limited volume driven by single trades, news not yet reflected in major feeds, or social media attention. Without headline confirmation, we cannot definitively attribute the move to any specific corporate event such as earnings, contract awards, regulatory approval, or financing announcements.

TDTH

Trident Digital Tech Holdings LtdTechnology

$2.56+$0.74

+40.7%

NASDAQ · Mkt cap $2.3 B

Trident Digital announced that CEO Soon Huat Lim will convert $8 million of founder debt into restricted Class B shares ahead of a transition to direct Nasdaq ordinary-share trading, a balance-sheet strengthening move that likely triggered the 40% premarket surge.

The company disclosed a significant capital restructuring: the founder is converting $8 million in outstanding debt into equity, coupled with a 240-for-1 share consolidation and a planned shift from American Depositary Receipt (ADS) trading to direct Nasdaq ordinary-share trading. This combination of debt reduction, founder commitment via equity conversion, and exchange listing upgrade typically signals management confidence and structural improvement for a nano-cap stock. Debt-to-equity conversions reduce financial burden and improve balance-sheet optics; share consolidation often precedes uplisting to meet minimum share-price requirements. For small-cap stocks, such moves can generate outsized enthusiasm among retail and momentum traders. The timing of the premarket surge aligns directly with the announcement, suggesting investor recognition of the positive technical and financial implications.

VRXA

Veraxa Biotech Holding AGHealthcare

$3.03+$0.84

+38.4%

NASDAQ · Mkt cap $260 M

VERAXA announced pipeline progress and an enhanced partnering strategy centered on its BiTAC platform on July 6, directly preceding the 38% surge, suggesting investor enthusiasm for the company's therapy approach and business development momentum.

Three press releases on July 6 outlined VERAXA's H1 2026 corporate update with emphasis on BiTAC (conditionally active T cell engagers) advancement and formal partnering initiatives. The headlines establish that BiTAC molecules are designated as the company's primary value drivers and will dominate pipeline development. This represents concrete strategic clarity and operational progress in a biotech firm with a defined therapeutic approach. For early-stage biotech stocks, clear articulation of pipeline prioritization, partnering activity, and technology differentiation typically drives investor reallocation. The magnitude of the gain (38%) suggests the market viewed this announcement as materially positive, though the headlines do not specify new partnerships, clinical milestones, or financing, which means the move may reflect sentiment shift rather than a single dramatic catalyst.

TTRX

Turn Therapeutics Inc.Healthcare

$9.71+$2.02

+26.3%

NASDAQ · Mkt cap $295 M

Turn Therapeutics announced completion of an interim Phase 2 analysis of GX-03 for atopic dermatitis with a data-driven expansion of the trial, directly triggering the 26% gain on positive clinical progress.

The company released two related announcements on July 7 describing a comprehensive interim analysis of its Phase 2 trial for GX-03 in atopic dermatitis, followed by an optimized Stage 2 design that expands the study. While the headlines do not disclose the actual efficacy or safety data from the interim review, the decision to expand rather than pause or terminate the trial is a positive signal that the interim results met sufficient thresholds to warrant larger-scale investigation. For a clinical-stage biotech company, progression and expansion of a Phase 2 program typically indicates the drug candidate is performing well enough to justify continued investment. The stock's strong reaction reflects investor optimism about the drug's potential and the company's forward trajectory in a competitive inflammatory skin disease market.

PHOE

Phoenix Asia Holdings Limited Ordinary SharesIndustrials

$24.56+$5.05

+25.9%

NASDAQ · Mkt cap $526 M

No news headlines were found in the last 48 hours, so the cause of Phoenix Asia Holdings' +25.88% gain cannot be attributed to a specific announced event; the jump likely reflects technical trading, delayed news coverage, or market speculation.

Yahoo Finance returned no headlines for PHOE in the past 48 hours, which means either no major news was released, or coverage has not yet propagated to the RSS feed. A +25.88% single-day move on a NASDAQ-listed stock is substantial and typically warrants explanation via earnings, guidance, M&A, regulatory approval, or a material business update. Without headline evidence, the catalyst remains unknown. Possible drivers include technical factors such as short covering or options-related gamma pressure, a rumor or social media catalyst not yet captured in mainstream news feeds, delayed disclosure of a significant announcement, or normal intraday volatility in a lower-volume or micro-cap name. Without access to order flow, insider activity, or late-breaking news outside Yahoo's RSS window, we cannot pinpoint the true cause.

BATL

Battalion Oil CorporationEnergy

$1.78+$0.36

+25.4%

BJDX

Bluejay Diagnostics, Inc.Healthcare

$1.45+$0.29

+25.0%

NASDAQ · Mkt cap $1.0 M

No news headlines were published in the last 48 hours about BJDX, so the 25% rally cannot be directly attributed to a named catalyst. The move likely reflects technical momentum, delayed market reaction to earlier news, or company-specific developments not yet picked up by major news feeds.

The absence of recent headlines matching this strong single-day gain is notable. For a micro-cap diagnostic company like Bluejay, price moves of this magnitude are often driven by small-volume trading in thinly traded securities, short covering, or technical breakouts rather than fundamental catalysts. Alternatively, the catalyst could be an internal announcement (earnings release, clinical trial update, or partnership news) that has not yet propagated to major financial news aggregators within the 48-hour window. Small biotech and diagnostic firms are also occasionally subject to retail trading interest or sector rotation that lifts multiple names without company-specific news. Without corroborating headlines or context, attributing this move to a specific event would be speculation.

AMPGZ

Amplitech Group, Inc. Series B Right

$1.20+$0.24

+25.0%

NASDAQ

AmpliTech canceled a planned equity offering and authorized a $10M stock buyback program instead, signaling management confidence and eliminating dilution risk, which drove the 25% gain in the Series B Right security.

The company announced it would terminate its at-the-market equity offering and replace it with a $10M buyback program authorized by the board for 24 months. Management framed this decision as reflecting confidence in record revenue, a growing order book, and anticipated margin expansion. For equity investors, a buyback is typically more accretive than a dilutive equity raise, and the cancellation of a planned offering removes overhang that had likely pressured the stock. Retail investors interpreted this as a bullish signal of management conviction in the business. The Series B Right security (AMPGZ) likely moved in sympathy with the common stock (AMPG), amplifying the percentage gain due to its smaller market cap and liquidity profile. The news directly addresses capital allocation, which is a concrete catalyst rather than speculation.

PYXS

Pyxis Oncology, Inc.Healthcare

$3.07+$0.61

+24.8%

NASDAQ · Mkt cap $214 M

No news headlines were found in the last 48 hours to explain the 24.80% gain in PYXS stock, leaving the specific catalyst unclear without additional context.

Pyxis Oncology experienced a significant single-day rally of nearly 25% despite the absence of any reported news in the prior 48 hours according to the search results provided. For clinical-stage or early-commercial oncology companies like PYXS, typical catalysts driving substantial intraday moves include clinical trial results announcements, FDA decisions or guidance, partnership or licensing deals, interim efficacy data releases, or strategic shifts in pipeline focus. Without confirmed headlines, the jump could reflect a delayed market reaction to news released slightly outside the search window, an unconfirmed rumor or social media discussion, technical trading activity, short-covering, or an announcement made through channels not immediately captured by standard news feeds. The stock's relatively low price point and small cap profile make it more susceptible to outsized percentage moves on modest absolute volume shifts.

EDHL

Everbright Digital Holding Limited Ordinary SharesCommunication Services

$4.94+$0.98

+24.7%

NASDAQ · Mkt cap $6.5 M

No news headlines were found in the last 48 hours, so the 24.75% gain likely reflects technical trading activity, short covering, or untracked announcements rather than a confirmed corporate event.

The absence of any news coverage in the 48-hour window preceding this significant rally makes attribution difficult. EDHL is a Chinese digital holding company with relatively modest liquidity on NASDAQ. A jump of this magnitude in a lightly-traded security can be driven by several factors unrelated to fundamental news: short-squeeze activity if the stock had elevated short interest, technical bounce-back from oversold conditions, delayed picking up of an overseas announcement not yet covered by Western financial news feeds, or retail trading momentum. Chinese stocks listed on U.S. exchanges sometimes experience delayed news flow between markets. Without evidence of earnings, guidance, partnerships, or regulatory developments, pinpointing the specific catalyst is not possible from the information available.

VACH

Voyager Acquisition Corp.Financial Services

$2.72+$0.53

+24.2%

SCLX

Scilex Holding CompanyHealthcare

$9.93+$1.86

+23.0%

NASDAQ · Mkt cap $40 M

Scilex surged 23% after announcing a binding term sheet for a $100 million strategic investment from iHolding Group LLP, with the news released on July 7 and initially driving a 7% gain on July 6.

On July 6, Scilex announced it had signed a binding term sheet for a proposed $100 million strategic investment from iHolding Group LLP, disclosed through both the parent company and its majority-owned subsidiary Semnur Pharmaceuticals. The announcement garnered an immediate 7% jump on July 6, and the stock continued climbing significantly on July 7, reaching a 23% gain for the day. The investment is described as supporting growth plans for the specialty pharmaceutical company focused on non-opioid pain management. The binding nature of the term sheet, combined with the substantial capital injection, likely drove investor enthusiasm around the company's financial runway and strategic positioning. The size and timing of the capital raise appears to have been viewed positively by the market despite the stock's prior performance.

AMPGR

Amplitech Group, Inc. Series A Right

$1.10+$0.20

+22.2%

NASDAQ

AmpliTech announced a $10 million stock buyback program and terminated a planned equity offering, a move interpreted as management confidence and bullish for existing shareholders, driving the 22% gain.

The company's board authorized a 24-month repurchase program while simultaneously canceling a previously announced at-the-market equity offering. This substitution is strategically significant because buybacks reduce share dilution and signal management confidence in the stock's undervaluation, whereas equity offerings would dilute existing shareholders. The company stated the buyback reflects confidence in record revenue, a growing order book, and anticipated margin expansion. Retail investors explicitly labeled this a "bullish combo" according to the headline, suggesting the market interpreted the signal as positive. The termination of the dilutive equity raise removes a near-term headwind, making the buyback announcement particularly favorable relative to the prior plan.

RKLZ

DEFIANCE DAILY TARGET 2X SHORT RKLB ETF

$3.54+$0.60

+20.4%

NASDAQ

No news headlines appeared in the last 48 hours, but RKLZ is a 2x inverse leveraged ETF tracking Rocket Lab (RKLB), so a sharp 20% gain indicates RKLB fell sharply on likely negative fundamental, technical, or market-wide pressure.

The absence of any news in the provided headlines makes it impossible to identify a specific catalyst from reporting. However, RKLZ's structure as a daily target 2x short inverse leveraged ETF means it gains when its underlying asset RKLB declines. A 20% gain in RKLZ implies roughly a 10% single-day drop in RKLB (accounting for leverage and compounding effects). Given the magnitude and rank as a top gainer, this likely reflects either a significant adverse development affecting Rocket Lab itself (operational issue, earnings miss, guidance cut, contract loss), broad market selloff in aerospace or growth stocks, or a major technical breakdown in RKLB's chart. Without headlines or access to RKLB-specific news on July 7, 2026, the proximate cause remains unconfirmed, though the leverage structure itself fully explains why RKLZ moved so sharply in percentage terms.

POAS

Phaos Technology Holdings (CaymHealthcare

$0.32+$0.05

+19.7%

AMEX · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 19.71% gain on POAS cannot be attributed to a specific disclosed catalyst; the move likely reflects technical trading, retail interest in the penny-stock name, or undisclosed news not yet picked up by major financial media.

The absence of recent news headlines is the key fact here. POAS is a micro-cap security trading at $0.32, and such stocks are prone to outsized moves on relatively modest volume or sentiment shifts, even without formal news catalysts. Possible explanations include a technical breakout attracting day traders, short covering, or a social-media-driven retail accumulation event. Alternatively, a material announcement—such as a business update, financing, or corporate action—may have occurred but not yet been indexed by the RSS feeds monitored. Without concrete evidence, attributing the move to any specific event would be speculation.

CRE

Cre8 Enterprise Limited Class A Ordinary SharesIndustrials

$3.28+$0.53

+19.3%

NASDAQ · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 19.27% gain on July 7 cannot be attributed to a specific announced event. The move likely reflects technical trading, delayed news discovery, or market speculation.

CRE8 Enterprise Limited experienced a substantial single-day gain of 19.27%, ranking among the top 21 gainers on NASDAQ, yet no news headlines appeared in the Yahoo Finance RSS feed within the relevant 48-hour window. This disconnect between significant price movement and reported news creates ambiguity about the catalyst. For smaller-cap stocks like CRE8, common drivers of unexplained rallies include short covering or squeeze dynamics, retail trading interest driven by social media rather than traditional news wires, technical chart breakouts, or delayed disclosure of material events that have not yet propagated through major financial news outlets. Without access to the company's press releases, insider trading reports, or SEC filings from that specific date, or confirmation of whether the stock carries high short interest, it is not possible to determine whether this was a fundamental or technical move.

FHTX

Foghorn Therapeutics Inc.Healthcare

$6.00+$0.95

+18.8%

NASDAQ · Mkt cap $401 M

No news headlines were found in the last 48 hours, so the 18.81% gain on FHTX likely reflects either a delayed market reaction to an untracked announcement, technical buying, or sector momentum in biotech.

The absence of any news in the Yahoo Finance RSS feed over the past two days creates ambiguity about the driver of today's strong gain. For a clinical-stage or early commercial biopharmaceutical company like Foghorn Therapeutics, typical catalysts include clinical trial data releases, regulatory decisions, partnership announcements, or shifts in investor sentiment around pipeline assets. Without headline evidence, the move could reflect several possibilities: a material announcement made outside tracked news channels, accumulation by large holders, rotation into biotech equities, or short covering if the stock had been shorted. The 18.81% single-day move is substantial enough to suggest something more than pure technicals, but confirmation requires information not present in this dataset.

SNAL

Snail, Inc. Class A Common StockCommunication Services

$3.64+$0.57

+18.6%

AGIO

Agios Pharmaceuticals, Inc.Healthcare

$44.01+$6.62

+17.7%

NASDAQ · Mkt cap $2.0 B

Agios jumped 17.71% after the FDA granted Priority Review to its Mitapivat supplemental application for sickle cell disease, with an approval decision expected by November 1, 2026.

The jump is directly attributable to FDA regulatory progress on Agios's lead candidate. Priority Review status accelerates the FDA's standard review timeline and signals the agency views the application favorably enough to expedite consideration. Multiple headlines confirm this is the primary catalyst, emphasizing that Mitapivat could become the first oral PK activator for sickle cell disease if approved. One headline mentions "profit-taking zone," suggesting the stock may have been poised for this jump and some traders are already taking gains, but the underlying driver is the regulatory milestone. The November 1 PDUFA goal date provides a clear timeline for the next catalyst. While one headline references Q2 earnings scrutiny, the bulk of coverage focuses on the FDA action, which is the newsworthy event driving the move.

FRTT

Fort Technology Inc. Common SharesConsumer Cyclical

$0.90+$0.13

+17.3%

NASDAQ · Mkt cap $11 M

No news headlines were available in the last 48 hours, so the 17.33% gain on FRTT likely reflects either technical trading activity, delayed announcement dissemination, or market speculation in a low-priced equity.

The absence of any recent news headlines makes it impossible to point to a specific catalyst for today's 17.33% jump. Fort Technology is trading at $0.90, placing it in the micro-cap territory where price action can be volatile and driven by factors other than fundamental news. Low-priced stocks are often susceptible to retail trading interest, short covering, or technical momentum plays. The gain ranks FRTT in the top 25 gainers for the day, suggesting it caught broader market attention, but without accompanying news coverage this could reflect a delayed earnings release, an announcement not yet picked up by Yahoo Finance RSS feeds, or pure technical/sentiment-driven momentum. Micro-cap stocks in this price range sometimes experience outsized moves on thin volume or algorithmic activity unrelated to company-specific developments.

JLHL

Julong Holding Limited Class A Ordinary SharesIndustrials

$4.32+$0.63

+17.1%

NASDAQ · Mkt cap $152 M

No news headlines were found in the last 48 hours for JLHL, so the 17.07% gain on July 7th cannot be directly attributed to a specific announced event. The move likely stems from technical factors, delayed news pickup, or market rumors.

The absence of any recent news headlines makes it difficult to pinpoint the exact cause of JLHL's sharp 17.07% jump to $4.32. For a relatively small-cap NASDAQ listing, this type of single-day move without accompanying news could reflect several possibilities. First, there may be a delayed news event that has not yet been indexed by the RSS feed, or news may have broken after market close on the prior day. Second, the move could be driven by technical factors such as short covering, algorithmic buying following a breakout, or movement in correlated securities. Third, unconfirmed rumors or social media activity sometimes precedes formal announcements. Without access to the underlying fundamentals or knowledge of JLHL's recent operating performance, we cannot determine whether this is a meaningful company development or a temporary sentiment shift.

IVA

Inventiva S.A.Healthcare

$4.56+$0.66

+16.9%

NASDAQ · Mkt cap $1.1 B

No news headlines were found in the last 48 hours for IVA, so the 16.92% gain cannot be directly attributed to a disclosed catalyst; the move may reflect technical trading, sector momentum, or undisclosed news.

Inventiva is a clinical-stage biopharmaceutical company focused on metabolic and liver diseases, a sector sensitive to clinical trial outcomes, regulatory decisions, and partnership announcements. The absence of news in the RSS feed does not rule out a catalyst occurring today or yesterday that has not yet propagated to Yahoo Finance headlines, or the move could reflect technical factors such as short covering, options-related hedging, or broader biotech sector strength. For small-cap biotech stocks like IVA, single-day swings of this magnitude are not uncommon even without disclosed news, particularly if the stock has low trading volume or high short interest. Without access to real-time news wires, SEC filings, or trading data, attribution remains speculative.

NETG

Leverage Shares 2x Long NET Daily ETF

$15.99+$2.31

+16.9%

NASDAQ

No news headlines were available in the last 48 hours, but NETG is a 2x leveraged ETF tracking Cloudflare (NET), so a strong rally in NET stock would directly amplify into a larger gain for this security.

The absence of news in the provided headlines does not explain the 16.92% jump on its own. However, NETG is a daily 2x leveraged long ETF on Cloudflare (NET), meaning it is structurally designed to deliver approximately double the daily percentage move of its underlying stock. If NET itself rallied roughly 8-9% on July 7, 2026, the leverage mechanism would produce a gain close to what we observe here. Without access to NET's price action or any breaking news about Cloudflare, we cannot confirm the specific catalyst—it could stem from positive earnings, analyst upgrades, sector momentum, or other market developments in NET—but the leverage structure of NETG explains why the percentage move is outsized relative to typical single-stock moves.

RDAC

Rising Dragon Acquisition Corp.Financial Services

$5.76+$0.81

+16.4%

NASDAQ · Mkt cap $35 M

No news headlines were found in the last 48 hours, so the +16.36% gain cannot be attributed to a specific announced event. The move likely reflects either delayed market reaction to an earlier announcement, a short squeeze, or technical trading in a low-priced SPAC.

The absence of any news in Yahoo Finance's RSS feed over the past two days means we cannot point to a specific catalyst such as earnings, merger developments, or regulatory action. Rising Dragon Acquisition Corp. is a special purpose acquisition company, a category known for sharp price swings driven by deal speculation, short covering, or retail trading momentum rather than fundamental news. The +16.36% single-day gain ranks it 29 among all movers, suggesting broad market attention, but without headlines this could reflect accumulated technical strength, options expiration dynamics, or market whispers about a target acquisition that have not yet reached mainstream press. It is also possible a significant announcement was made but has not yet been indexed by Yahoo Finance's feed system.

ILLR

Triller Group Inc.Technology

$2.44+$0.33

+15.6%

NASDAQ · Mkt cap $20 M

No news headlines were found in the last 48 hours, so the 15.64% gain cannot be attributed to a specific announced catalyst. The move is likely driven by technical factors, sector rotation, or unindexed market rumors.

The absence of any news in the Yahoo Finance RSS feed for the past 48 hours means we cannot point to an earnings beat, partnership announcement, regulatory approval, or other discrete event to explain ILLR's jump to the 30 biggest gainer spot. Triller Group is a microcap entertainment and social media company that historically exhibits high volatility. A move of this magnitude without accompanying headline news typically reflects one of several dynamics: technical mean reversion following a recent decline, short covering or a squeeze event, sector-wide momentum in social media or creator-economy stocks, or retail investor interest catalyzed by social platforms rather than traditional newswire coverage. Without access to trading volume data, short interest levels, or broader market context, we cannot definitively identify which of these forces drove the move today.

CMMB

Chemomab Therapeutics Ltd.Healthcare

$2.77+$0.37

+15.4%

NASDAQ · Mkt cap $15 M

No headlines were found in the last 48 hours, so the 15.42% gain on CMMB cannot be tied to a specific news event. The move likely reflects either a delayed market reaction to an earlier announcement, technical trading, or market rumor.

The absence of recent headlines makes it difficult to identify a concrete catalyst for today's 15.42% jump in CMMB. Chemomab Therapeutics is a clinical-stage biotech company focused on immunology and fibrosis, so typical drivers for this sector include clinical trial data releases, regulatory updates, partnership announcements, or changes in cash runway expectations. Given that no news appears in the 48-hour window, the move could reflect a reaction to an announcement made before the snapshot window, short covering in a thinly traded microcap, technical breakout trading, or unconfirmed market rumors. Without access to the broader context of the stock's recent history or intraday trading patterns, attribution remains speculative.

SOXS

Direxion Daily Semiconductor Bear 3X ETF

$4.80+$0.64

+15.2%

AMEX

SOXS surged 15.25% because the semiconductor sector fell sharply on July 7th, 2026; as a 3x inverse ETF, it gains when chip stocks decline, and the only available headline mentions AI server stocks rallying on July 6th, suggesting a sector reversal occurred overnight.

SOXS is a leveraged inverse ETF that moves 3x in the opposite direction of the semiconductor index. A 15.25% gain indicates the underlying semiconductor sector dropped roughly 5% or more on July 7th. The provided headline from July 6th shows Dell and AI infrastructure names rallying, which would normally support semiconductor stocks. However, no July 7th headlines are included in the data. The sharp overnight reversal from bullish sentiment to a semiconductor decline is the most likely explanation, though the specific catalyst for the sector reversal is not documented in the available news. Possible causes include broader market weakness, a Fed policy shift, or a negative semiconductor-specific announcement that occurred after the last headline timestamp, but these remain inference rather than confirmed fact.

IMMX

Immix Biopharma, Inc.Healthcare

$12.02+$1.57

+15.0%

NASDAQ · Mkt cap $985 M

No news headlines were found in the last 48 hours for IMMX, so the 15% gain likely reflects a delayed market reaction to an earlier announcement, sector momentum, or technical factors in a biotech stock with typically high volatility.

The absence of recent headlines despite a substantial 15% single-day move is notable and limits causal certainty. IMMX is a clinical-stage biopharmaceutical company, a sector known for sharp price swings driven by trial results, regulatory decisions, partnership announcements, or broader biotech sentiment shifts. The gain could reflect a delayed market reaction to news released more than 48 hours prior, positive developments in an ongoing clinical program, short covering in a volatile stock, or positive spillover from the broader biotech or healthcare sector. Without contemporaneous headlines, we cannot identify a specific triggering event. Investors should check press releases directly from the company's investor relations site or search for announcements that may not have appeared in the Yahoo Finance RSS feed within the specified window.

KTWOR

K2 Capital Acquisition Corporation Rights

$0.23+$0.03

+14.9%

NASDAQ

No news was found in the last 48 hours, so the 14.94% gain likely reflects either a technical or market microstructure event typical of low-priced SPAC-related securities, or delayed reaction to an earlier announcement not captured in the headline feed.

K2 Capital Acquisition Corporation Rights is a SPAC-related instrument trading at a very low price point where modest dollar moves can produce large percentage gains. The absence of recent news headlines does not rule out a catalyst; it may indicate the move was triggered by older news not refreshed in the RSS feed, technical trading (short covering, thin liquidity rebound), or corporate action related to the SPAC's merger timeline or extension vote. Rights offerings are sensitive to developments affecting the parent SPAC's merger prospects or shareholder voting dynamics. Without access to the company's recent filings, merger status, or pre-market chatter, the specific driver cannot be determined from the evidence at hand.

RGTZ

Daily Target 2X Short RGTZ ETF

$4.86+$0.63

+14.9%

NASDAQ

No news headlines available in the last 48 hours, but RGTZ is a 2X short leveraged ETF, so a 14.89% gain likely reflects a sharp decline in its underlying index or asset that the fund is designed to profit from.

RGTZ is a Daily Target 2X Short ETF, meaning it is constructed to deliver twice the inverse daily return of its underlying benchmark. With no recent news headlines provided, the move cannot be attributed to company-specific or fund-specific announcements. Instead, this gain almost certainly stems from a significant decline in the underlying asset or index that RGTZ tracks inversely. On a day when RGTZ rose 14.89%, its underlying reference asset likely fell roughly 7-8% (accounting for the 2X leverage and daily reset mechanics of leveraged ETFs). This type of move is typical for short ETFs during broad market selloffs or sector-specific downturns. Without access to the underlying asset's price action or market conditions on July 7, 2026, the specific catalyst remains unknown, but the mechanics of the ETF structure fully explain why it moved sharply higher on a day with no identifiable news.

ZTG

Zenta Group Company Limited Class A Ordinary SharesIndustrials

$2.28+$0.29

+14.6%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours, so the 14.57% gain on ZTG is unexplained by reported corporate announcements or market events in the provided data.

The absence of any headlines in the last 48 hours makes it impossible to attribute this move to a specific catalyst such as earnings, guidance, a contract award, or strategic announcement. For a micro-cap stock like ZTG trading near $2.28, typical drivers of single-day 14% rallies include technical rebounds from oversold conditions, short covering, retail investor coordination on social media, delayed disclosure of material news not yet picked up by major outlets, or shifts in sector sentiment affecting the broader market segment in which it trades. Without access to real-time trading volume, institutional flows, or social media activity, we cannot definitively determine which of these mechanisms was at work. The ranking as the 36th biggest gainer suggests this was a noteworthy move relative to the broader market that day, but without corroborating headlines or known corporate events, the specific cause remains unknown.

NAAS

NaaS Technology Inc.Consumer Cyclical

$3.49+$0.44

+14.4%

NASDAQ · Mkt cap $59 M

No news headlines were found in the last 48 hours, so the 14.43% gain on NAAS likely stems from technical factors, sector momentum, or undisclosed company announcements not yet indexed by Yahoo Finance.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for the 14.43% jump. NaaS Technology is a small-cap stock trading at $3.49, which typically means it can be more volatile and responsive to technical factors, short covering, or retail trading activity. Possible categories of cause include a delayed earnings release or guidance update not yet reflected in the news feed, sector-wide momentum in technology or software-as-a-service stocks, or a technical rebound from oversold conditions. Without corroborating headline data, any specific attribution would be speculation. The rank as the 37th biggest gainer suggests it is among hundreds of stocks moving today, which is consistent with either broad sector strength or idiosyncratic stock-level news that has not yet propagated to major financial news sources.

IONZ

Defiance Daily Target 2x Short IONQ ETF

$3.45+$0.43

+14.1%

NASDAQ

No recent news headlines were found to explain the move, but IONZ is a 2x inverse leveraged ETF on IONQ, so a 14% gain likely reflects a sharp decline in the underlying IONQ stock over the period.

No headlines from the last 48 hours were available to identify a specific catalyst. However, IONZ is a structured product designed to move inversely to IONQ (IonQ, a quantum computing company) with 2x daily leverage. This means IONZ gains when IONQ falls and amplifies those moves by approximately double the daily percentage decline. A 14% gain in IONZ would correspond to roughly a 7% single-day drop in IONQ, suggesting significant negative price action in the underlying quantum computing stock. The cause of IONQ's decline remains unknown from the provided information—it could stem from earnings disappointment, sector weakness, competitive developments, or other market dynamics. Leveraged inverse ETFs also carry daily reset mechanics that can create tracking differences over time, though a same-day 14% move is primarily driven by underlying price movement.

ALIT

Alight, Inc.Technology

$19.04+$2.33

+13.9%

NYSE · Mkt cap $525 M

Alight jumped 13.94% on July 7 following a positive ISM Services PMI report released July 6 that showed continued expansion in the business services sector, which is directly relevant to Alight's operations as a business services and HR solutions provider.

The headline explicitly connects Alight's stock surge to the ISM Services PMI report released on July 6 afternoon, which indicated expansion in the business services sector. Alight operates in HR consulting, benefits administration, and business process outsourcing—sectors directly tied to overall business services health. When PMI data shows economic strength and expansion in services, companies like Alight that derive revenue from corporate clients typically see positive sentiment, as it suggests companies will maintain or increase spending on HR and workforce solutions. The stock's ranking as the 39th biggest gainer suggests it was part of a broader sector rotation or relief rally triggered by the macro data. This is a straightforward positive macro-to-micro connection rather than company-specific news.

TELA

TELA Bio, Inc.Healthcare

$0.89+$0.11

+13.7%

NASDAQ · Mkt cap $29 M

No news headlines were found in the last 48 hours, so the 13.67% gain likely reflects a technical bounce, short covering, or delayed market reaction to an untracked development or regulatory event for this biotech stock.

Yahoo Finance returned no headlines for TELA Bio in the 48-hour window around this +13.67% move on July 7, 2026. For a small-cap biotech trading at $0.89, price swings of this magnitude are not uncommon even without fresh news. The most probable explanations fall into a few categories: first, a delayed or unindexed news event (clinical trial result, financing announcement, or FDA communication) that reached investors but was not captured in the RSS feed; second, technical bounce or short covering if the stock had fallen sharply in prior days; third, a broader sector rally in biotech that lifted the stock alongside peers. Without access to the company's news releases, SEC filings, or real-time market data beyond the price action, we cannot pinpoint the specific catalyst. Biotech stocks at this price point are particularly sensitive to clinical or regulatory milestones, financing events, and short-squeeze dynamics.

ODVWZ

Osisko Development Corp. Warrant expiring 5/27/2027Basic Materials

$0.06+$0.01

+13.6%

NASDAQ

Osisko Development Corp. exercised approximately $1.25 million in warrants on Falco Resources, a liquidity event that likely drove warrant value higher as it signals active conversion and reduces warrant overhang uncertainty.

The headline indicates Falco Resources announced receipt of approximately $1.25 million in aggregate proceeds from warrant exercises, with Osisko Development Corp. performing an early exercise. For a warrant security trading at $0.06, warrant exercise announcements are material because they represent actual capital deployment and reduction of dilution risk. When warrant holders exercise in-the-money positions, it can signal confidence in the underlying and removes the uncertainty around whether those warrants will eventually be converted. This exercise likely improved sentiment around the warrant's intrinsic value and the underlying Falco position. The 13.64% single-day gain is consistent with a modest-sized warrant responding to positive conversion news, though the absolute price movement in nominal terms remains small given the warrant's low dollar value.

MRKR

Marker Therapeutics, Inc.Healthcare

$1.68+$0.20

+13.5%

NASDAQ · Mkt cap $19 M

No news headlines were available in the last 48 hours, so the 13.51% jump cannot be attributed to a specific announced catalyst. The gain may reflect technical trading, delayed news pickup, or sector momentum.

The absence of recent news makes it impossible to pinpoint a single cause for Marker Therapeutics' 13.51% daily gain. For a small-cap biotech company trading near $1.68, typical drivers of sudden moves include clinical trial results, regulatory approvals or setbacks, partnership announcements, or insider activity. The stock's modest price point and its ranking as the 42nd biggest gainer suggests this is a low-liquidity name where relatively modest trading volume can produce outsized percentage moves. Without evidence of a specific news event, the jump could reflect technical buying pressure, delayed market reaction to older news not captured in the 48-hour window, sector rotation into biotech, or speculative positioning in a thinly traded stock.

TDIC

Dreamland Limited Class A Ordinary SharesCommunication Services

$4.07+$0.48

+13.4%

NASDAQ · Mkt cap $4.0 M

No news headlines were found in the last 48 hours for TDIC, so the 13.37% gain on July 7 cannot be attributed to a specific disclosed event; the move likely reflects technical trading, delayed news, or market sentiment unrelated to public announcements.

The absence of recent news headlines creates a direct evidence gap. TDIC shares jumped 13.37% to rank 43rd among daily gainers on NASDAQ, yet no corresponding financial announcements, earnings releases, regulatory actions, or corporate developments appear in the available news feed. This disconnect suggests several possible explanations worth considering as inference rather than fact. First, the move could reflect technical trading activity such as short covering, options expiration dynamics, or algorithmic rebalancing unrelated to fundamentals. Second, a material announcement may have occurred but not yet propagated through the RSS feed monitored here. Third, the stock could be responding to sector-wide sentiment, insider activity, or market rumors not yet formalized in press releases. Without access to the company's investor relations announcements, SEC filings, or real-time news wires beyond the Yahoo Finance RSS snapshot, pinpointing a specific catalyst is not possible.

LYEL

Lyell Immunopharma, Inc.Healthcare

$15.91+$1.87

+13.3%

NASDAQ · Mkt cap $386 M

The news provided does not mention LYEL. A board appointment at AbCellera, a separate biotech company, is unrelated to LYEL's 13% gain today. The cause remains unknown based on available information.

The only headline provided concerns AbCellera Appoints Dr. Lynn Seely to its Board of Directors, which is a separate entity from Lyell Immunopharma and does not directly explain LYEL's stock movement. It is possible there is an indirect connection through shared investors, partnerships, or sector sentiment, but this is not established by the headline. For a biotech stock like LYEL with a 13% intraday jump, typical catalysts include clinical trial data, regulatory approvals, partnership announcements, funding news, or analyst upgrades. Without headlines covering LYEL specifically, we cannot identify which category of catalyst likely drove today's move. The gain is substantial enough to suggest a material corporate event rather than pure technical trading.

XHLD

TEN Holdings, Inc. Common StockCommunication Services

$2.13+$0.25

+13.3%

NASDAQ · Mkt cap $92 M

No news headlines were found in the last 48 hours, so the 13.3% gain likely reflects technical trading, a delayed announcement, or market speculation rather than a confirmed catalyst.

The absence of recent news makes it difficult to pinpoint a specific cause for XHLD's 13.3% jump. TEN Holdings is a relatively small-cap stock trading on NASDAQ, and moves of this magnitude in stocks without concurrent headline coverage often stem from technical factors such as short covering, options expiration effects, or algorithmic trading. Alternatively, the catalyst could be a delayed market reaction to news released before the 48-hour window, an earnings beat or company announcement not yet widely picked up by major financial feeds, or retail or institutional accumulation based on undisclosed fundamental developments. Without corroborating headlines, we cannot distinguish between these possibilities.

GCTK

GlucoTrack, Inc.Healthcare

$0.36+$0.04

+13.2%

NASDAQ · Mkt cap $3.7 M

No news headlines were found in the last 48 hours, so the 13.24% gain likely reflects technical trading, a delayed announcement, or sector-wide movement that has not yet appeared in major financial news feeds.

GlucoTrack is a micro-cap stock trading at $0.36, and no recent news headlines are available to explain today's sharp 13.24% gain and rank as the 46th biggest gainer. In the absence of documented catalysts, several mechanisms could drive such a move in this price range. Micro-cap stocks are prone to technical rebounds after prior sell-offs, especially if they retrace key support levels or if short covering occurs. Alternatively, the move could reflect a delayed or localized news item not yet indexed by the RSS feeds checked, such as a clinical trial update, partnership announcement, or regulatory filing specific to diabetes management technology. A sector rotation favoring healthcare or diagnostic devices could also contribute. Without access to the actual news or company filings from the relevant timeframe, any specific explanation remains speculative.

Versus Systems Inc.Technology

$1.59+$0.19

+13.2%

NASDAQ · Mkt cap $8.3 M

No news headlines were published in the last 48 hours, so the 13.21% jump in VS stock cannot be attributed to a disclosed event. The move likely reflects technical trading, delayed news absorption, or market speculation.

The absence of recent news headlines means we cannot point to a specific catalyst such as earnings, partnerships, or product announcements. Versus Systems is a micro-cap gaming and esports technology company, and stocks in this category are often thinly traded and prone to sharp moves on modest volume, intraday momentum shifts, or social media attention. Possible explanations include a delayed market reaction to older news, short covering, algorithmic trading, or retail investor interest driven by factors not yet reflected in major financial headlines. Without access to intraday volume data, insider activity, or commentary from market observers, attributing this move to a particular cause would be speculation.

NGNE

Neurogene Inc.Healthcare

$36.80+$4.24

+13.0%

NASDAQ · Mkt cap $753 M

Neurogene announced inducement grants under Nasdaq listing rules on July 6, a procedural equity issuance that likely triggered modest buying interest, contributing to the 13% single-day jump on July 7.

The only headline provided is a July 6 announcement of inducement grants under Nasdaq Rule 5635(c)(4), which permits companies to grant equity to new employees as an incentive to join. This is a routine corporate action for clinical-stage biotech firms and does not represent material clinical, regulatory, or business news. The headline text is truncated and provides no detail on grant size, vesting terms, or strategic context. A 13% single-day gain on a purely administrative equity announcement is notable and suggests either concurrent positive sentiment in the biotech sector, technical buying in a less-liquid stock, or other market-moving information not captured in the headline snippet. Without fuller context, it is difficult to attribute the move definitively to the grant announcement alone; this may be coincidental timing.

IVVD

Invivyd, Inc.Healthcare

$0.94+$0.11

+12.9%

NASDAQ · Mkt cap $283 M

Invivyd surged 12.93% likely on relief that the company has 12 months to pursue full FDA approval before PEMGARDA's emergency authorization expires on June 29, 2027, rather than facing immediate de-authorization.

The news establishes that the HHS announced termination of the COVID-19 EUA declaration effective June 29, 2027, which means PEMGARDA's emergency status will end unless full FDA approval is secured beforehand. The stock initially dropped on this news, but the 12.93% gain on July 7 suggests a reassessment or clarification. The most plausible explanation is that investors initially panicked at the EUA termination announcement but then recognized that Invivyd has a full year to pursue standard FDA approval, which is a realistic pathway rather than an outright loss of market access. The advanced notice provides a concrete timeline for the company to execute its regulatory strategy, which may have been viewed as more constructive than an immediate or ambiguous deadline. This represents a material milestone with defined optionality rather than an existential threat.

DTIL

Precision BioSciences, Inc.Healthcare

$9.25+$1.02

+12.3%

NASDAQ · Mkt cap $235 M

No news headlines were found in the last 48 hours, so the 12.33% gain likely reflects a delayed market reaction to an earlier announcement, technical buying, or sector momentum in biotech.

Precision BioSciences is a gene-editing biotech company, and a 12.33% single-day gain without accompanying headlines in the immediate window suggests either a lag between the triggering event and news indexing, or the move is driven by factors outside traditional press releases. Biotech stocks of this type commonly respond to clinical trial updates, partnership announcements, FDA regulatory decisions, or broader sector rallies in gene therapy. Without visible headlines, the most likely explanations are that news broke before the 48-hour window, an announcement circulated through investor channels before broader media pickup, or the move reflects algorithmic rebalancing or positive sentiment in the gene-editing space. We cannot rule out a delayed market response to an earlier earnings report or regulatory filing.

Biggest Losers

Tue, Jul 7, 2026 50

RVNL

GraniteShares 2x Long RIVN Daily ETF

$27.87−$16.26

-36.9%

NASDAQ

No news headlines were found in the last 48 hours, but RVNL is a 2x leveraged long ETF tracking Rivian stock, so a sharp decline in Rivian shares would amplify into an even steeper drop in this fund, likely driven by negative Rivian news or market sentiment not captured in the provided headlines.

The absence of any Yahoo Finance headlines in the last 48 hours makes direct causation impossible to establish from the provided evidence. However, RVNL is a leveraged ETF designed to deliver 2x daily returns of the Rivian Automotive stock price. A 36.85% decline in this fund is consistent with approximately an 18% drop in underlying Rivian shares, amplified by the fund's 2x leverage structure. Possible catalysts for such a move in Rivian itself could include negative earnings guidance, production delays, competitive announcements, broader EV sector weakness, or general market selloff pressure. Without specific news headlines, the most likely explanation is that Rivian experienced a significant negative catalyst that this headline feed failed to capture, or the move occurred in after-hours trading before news dissemination.

JCICX

JPMorgan U.S. GARP Equity Fund

$60.94−$30.02

-33.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 33% drop cannot be directly attributed to a reported event. The decline likely stems from broader market weakness, fund redemptions, or a lag in news indexing.

JCICX is a mutual fund (not an individual stock), which means its price reflects net asset value and investor flows rather than company-specific events. A 33% single-day drop in a fund is extreme and unusual. Without recent news, the most plausible causes are: (1) a major market correction or sector crash affecting the fund's underlying holdings, particularly large-cap growth or GARP-style equities; (2) a significant fund redemption wave or operational event like a split or reclassification; or (3) a data lag where relevant news has not yet been indexed by the RSS feed. Mutual fund prices can also lag or spike during market dislocations. The absence of headlines in a major news feed during such a dramatic move suggests either an exogenous market event affecting equities broadly, or the news has simply not yet propagated to the sources checked.

JIGZX

JPMorgan U.S. GARP Equity R2

$61.51−$30.01

-32.8%

NASDAQ

No news headlines were published in the last 48 hours, so the cause of the -32.79% drop cannot be directly attributed to a specific announcement or event based on available information.

The absence of recent news headlines makes it difficult to pinpoint a definitive catalyst for JIGZX's sharp decline. However, this is a JPMorgan U.S. GARP (Growth at a Reasonable Price) equity fund, which is a mutual fund product that can be affected by several mechanisms unrelated to breaking news. Possible explanations include a significant market downturn in growth-oriented equities that the fund's holdings are particularly exposed to, a large redemption wave or fund liquidation that forced asset sales, a distribution or NAV adjustment, or shifts in market sentiment toward the growth/value style that GARP funds target. Without specific news or knowledge of fund-specific events like closures or restructurings, the underlying cause remains speculative and likely relates either to broad market movements affecting the fund's equity holdings or to fund-specific operational factors rather than a single newsworthy event.

WFF

WF Holding LimitedIndustrials

$2.03−$0.94

-31.6%

NASDAQ · Mkt cap $20 M

WFF dropped 31.65% on July 7, 2026, but no news headlines were published in the prior 48 hours, so the specific catalyst cannot be identified from available reporting.

The absence of news in the last 48 hours suggests the trigger was either a delayed market reaction to an older announcement, an intraday rumor or market development not yet picked up by Yahoo Finance RSS feeds, or a technical/liquidity event. A 31.65% single-day decline in a stock trading near $2 is severe and could reflect several scenarios typical for lower-priced securities: disappointing earnings or guidance released outside the headline window, a debt restructuring announcement, insider selling or lock-up expiration, rating downgrades, regulatory setbacks, or broad sector weakness in WF Holding's business area. Without access to company filings, press releases, or deeper market data for July 7, the exact cause remains unconfirmed. The move ranks among the day's largest losers, suggesting market-wide awareness of the catalyst, but the specific event has not been captured in the recent RSS feed.

JIGAX

JPMorgan U.S. GARP Equity Fund Class A

$66.91−$29.93

-30.9%

NASDAQ

No news headlines were found in the last 48 hours to explain the 30.91% drop in JIGAX, suggesting either a delayed market reaction, technical correction, underlying fund holdings weakness, or an untracked announcement.

JIGAX is a mutual fund (JPMorgan U.S. GARP Equity Fund Class A), not an individual stock, so large single-day declines typically reflect sharp drops in its underlying net asset value driven by the performance of its equity holdings. The absence of any Yahoo Finance headlines in the last 48 hours is notable but not conclusive—fund price declines can lag portfolio stress by hours or days, or may reflect broader market moves not yet surfaced in news aggregators. Possible catalysts include a significant decline in a major portfolio holding, a sector rotation out of growth or quality equity, broader market volatility unrelated to JIGAX-specific news, or a technical event such as dividend adjustment or fund rebalancing. Without access to the fund's current holdings or intraday market movements, we cannot narrow this further.

JGIRX

JPMorgan U.S. GARP Equity Fund

$68.16−$29.91

-30.5%

NASDAQ

No news headlines were available in the last 48 hours, so the -30.50% decline cannot be directly attributed to a specific announced catalyst. The drop in this JPMorgan mutual fund likely reflects broad market sell-off, portfolio rebalancing, or net outflows.

The absence of any news in the 48-hour window preceding this sharp decline suggests the move was not triggered by fund-specific announcements, earnings, or strategy changes. JGIRX is a GARP (Growth at a Reasonable Price) equity fund, so its performance is primarily driven by movements in its underlying stock holdings and broader market conditions. A -30.50% single-day loss of this magnitude in a diversified equity mutual fund is unusual and points toward either a severe market-wide event (equity market crash, flash crash, or technical error), significant fund-specific stress such as mass redemptions, or possibly a delayed news event not yet captured in the RSS feed. Without access to market data or subsequent reporting, the specific trigger remains unknown. Mutual funds can also experience pricing anomalies or administrative errors that are later corrected.

JGISX

JPMorgan U.S. GARP Equity Fund

$68.17−$29.91

-30.5%

NASDAQ

No news headlines were published in the last 48 hours, so the 30.5% drop cannot be directly attributed to a named catalyst; the move may reflect a sharp market correction, fund outflows, or delayed reaction to earlier earnings or market stress.

JGISX is a mutual fund (JPMorgan U.S. GARP Equity Fund), not an individual stock, so its net asset value tracks the performance of its underlying portfolio of growth-at-a-reasonable-price holdings. A 30.5% single-day drop is extraordinary and highly unusual for a diversified equity fund. Without news headlines to anchor the cause, several types of events could explain it: broad equities selloff (market correction or crash), significant fund-specific stress (large redemptions, error in NAV calculation, or structural issue in the fund), delayed reaction to poor earnings from major holdings, or isolated market dysfunction. The absence of any headline coverage is itself notable and suggests either that the move occurred after major news wire closes or that something fund-specific rather than market-wide occurred.

KIDZ

KIDZ AI Inc.Consumer Defensive

$0.74−$0.31

-29.9%

NASDAQ · Mkt cap $638 K

KIDZ AI announced a major award win and new robotics platform launch on July 6, yet the stock fell 29.90% the next day, suggesting the market either viewed the news as priced-in, underwhelming, or was driven by unrelated selling pressure or profit-taking.

The headline from July 6 reports positive news: KIDZ AI won the 2026 EdTechX Award for the Americas and launched KIDZBot, an AI-native robotics platform for education. Normally such recognition and product launches support or lift stock prices. The substantial 29.90% drop on July 7 despite this favorable announcement is counterintuitive. Possible explanations include: (1) the market had already priced in award expectations and product launch timing, making the actual news a disappointment relative to elevated expectations, (2) the announcement lacked concrete revenue guidance, customer commitments, or near-term monetization details that would justify the stock's valuation, or (3) the decline stems from unrelated factors such as broader sector rotation out of EdTech or AI stocks, selling pressure from insiders or early investors, or a negative development not captured in the provided headlines. Without additional context on the company's valuation, short interest, or concurrent market movements in the EdTech space, the gap between positive news and sharp decline remains unexplained by the headlines alone.

JPGSX

JPMorgan U.S. GARP Equity Fund Class I

$70.63−$29.87

-29.7%

NASDAQ

No news headlines were found in the last 48 hours, so the 29.72% decline likely reflects a broader market selloff, fund redemptions, or a sharp drop in the fund's underlying equity holdings.

JPGSX is a mutual fund (JPMorgan U.S. GARP Equity Fund Class I) rather than an individual stock, so its daily price movements reflect the net asset value of its portfolio holdings. Without any news in the past 48 hours specifically tied to JPMorgan or this fund, the sharp decline most likely stems from one of three categories: (1) a significant market-wide selloff affecting growth or large-cap equities that dominate a GARP (Growth At Reasonable Price) strategy, (2) large investor redemptions triggering fund sales to meet outflows, or (3) a negative earnings surprise or guidance cut from one or more major holdings that was announced before the 48-hour window. Because no headlines appear here, the precise trigger cannot be identified from the evidence available.

ARCLR

ARC Group Acquisition I Corp Right

$0.17−$0.07

-28.4%

HODO

Brag House Holdings, Inc.Technology

$1.78−$0.66

-27.0%

NASDAQ · Mkt cap $33 M

No news headlines were found in the last 48 hours, so the 27% drop likely stems from a company-specific event, sector rotation, technical selling, or a delayed announcement not yet captured by RSS feeds.

The absence of recent news makes it impossible to pinpoint a specific catalyst for HODO's sharp 27% decline. For a micro-cap or small-cap stock like Brag House Holdings, large single-day moves often reflect thin liquidity, technical breakdown through support levels, margin calls in retail portfolios, or unannounced company developments that have not yet been widely reported. Without access to after-hours filings, investor calls, or social media chatter, the most likely causes remain speculative: earnings disappointment, insider selling signals, financing dilution, covenant violations, or competitive pressures. The absence of news coverage itself could indicate the stock trades with limited institutional attention, making it more prone to momentum-driven swings.

SECZ

Securitize Corp.Technology

$8.06−$2.82

-25.9%

NYSE · Mkt cap $1.2 B

SECZ fell 25.92% despite a positive partnership announcement with Continental Stock Transfer on July 7th; the magnitude of the drop suggests either a market-wide tech selloff, a delayed negative catalyst from July 6th, or investor skepticism about the partnership's value.

The most recent headline from July 7th announces Securitize's selection as a preferred tokenization partner with Continental Stock Transfer, which frames the company favorably by expanding its issuer base access to regulated digital securities infrastructure. This is ostensibly positive news released on the same day as the major decline, which creates a disconnect. The second headline about NYSE Trump accounts and $1,000 eligibility appears to be a generic market update unrelated to SECZ. No earnings miss, guidance cut, or negative announcement appears in the provided headlines. The 25.92% drop could reflect profit-taking after a prior run-up, sector rotation out of fintech or blockchain-adjacent stocks, or an unmentioned negative development from July 6th that the headlines did not capture. Without visibility into pre-market context or competing news, the exact trigger remains unclear.

SRXH

SRX Global Inc.Technology

$1.35−$0.47

-25.8%

EDBL

Edible Garden AG IncorporatedConsumer Defensive

$0.09−$0.03

-24.9%

WHLR

Wheeler Real Estate Investment Trust, Inc.Real Estate

$0.56−$0.18

-24.7%

NASDAQ · Mkt cap $942 K

No news headlines were found in the last 48 hours, so the 24.75% drop cannot be attributed to a specific announced event. The decline likely stems from technical selling, a delayed reaction to prior news, or market-wide pressures affecting small-cap REITs.

Wheeler Real Estate Investment Trust is a small-cap REIT trading at $0.56, a price level often associated with liquidity constraints and higher volatility. The absence of any recent news headlines in the 48-hour window means we cannot point to an earnings miss, dividend cut, covenant breach, or other fundamental trigger for the sharp decline. Real estate investment trusts of this size are sensitive to changes in interest rate expectations, credit conditions, and sector sentiment. The move could reflect a delayed market reaction to an older announcement, forced selling by a distressed holder, technical breakdown below a support level, or broader weakness in the small-cap REIT space. Without access to intraday trading data or news from prior periods, pinpointing the catalyst is difficult.

ABTC

American Bitcoin CorpFinancial Services

$6.52−$1.97

-23.2%

SBEV

Splash Beverage Group, Inc.Consumer Defensive

$0.16−$0.05

-23.2%

AMEX · Mkt cap $2.5 M

Splash Beverage Group announced an exclusive global licensing deal for CannEpil, an epilepsy therapy, but the market sold off sharply, suggesting investor skepticism about the strategic fit or execution risk of a beverage company pivoting into biopharma.

The company issued a press release on July 7 announcing an exclusive global licensing agreement with Argent BioPharma for CannEpil, a cannabis-derived epilepsy treatment with European patient access and FDA engagement. This represents a significant pivot for a beverage-focused business into pharmaceutical development. While the deal itself is factual and was announced as positive news by the company, the market's 23-36% intraday sell-off suggests substantial investor skepticism. Possible reasons include doubt about management's capability to execute in biopharma, concerns about dilution or capital requirements, regulatory uncertainty around cannabis-derived therapeutics, or skepticism about the deal's commercial viability. The disconnect between corporate messaging (framed as an opportunity) and market reaction (sharp decline) indicates the deal is viewed as value-destructive rather than accretive, though the headlines do not explicitly state market concerns.

FXHO

UTime LimitedTechnology

$15.10−$4.45

-22.8%

NASDAQ · Mkt cap $54 M

No news headlines were found in the last 48 hours for FXHO, so the 22.76% drop cannot be directly attributed to a reported event. The decline likely stems from technical selling, delayed market reaction to an untracked announcement, or sector headwinds.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to connect the sharp 22.76% single-day loss to a specific catalyst. For a micro-cap or thinly traded stock like UTime Limited, intraday moves of this magnitude can occur from several sources: technical breakdown below support levels, liquidation pressure from a single investor or fund holder, undisclosed insider activity, delayed reaction to news published outside major financial feeds, or sector-wide volatility affecting similar companies. Without access to real-time order flow, regulatory filings, or social media discussions, we cannot distinguish between these scenarios. The magnitude of the move suggests material uncertainty rather than random noise, but the lack of attributed news means the specific driver remains unknown.

ZSQR

Coeptis Therapeutics Holdings, Inc.Technology

$8.49−$2.50

-22.7%

NASDAQ · Mkt cap $218 M

No headlines were found in the last 48 hours, so the 22.75% drop cannot be directly tied to announced news; the decline may reflect a clinical setback, market sentiment shift, or other undisclosed event typical for small-cap biotech stocks.

Coeptis Therapeutics is a clinical-stage biopharmaceutical company, and no news headlines appeared in the last 48 hours to explain the sharp 22.75% decline. For biotech companies of this size and stage, significant single-day drops are typically triggered by clinical trial failures, safety concerns, regulatory rejections, financing dilution announcements, or management changes. The absence of any news in the provided feed does not mean nothing happened—the company may have issued a press release that has not yet propagated to Yahoo Finance RSS, or the market may be reacting to information from private channels or earlier announcements that only now are being priced in. Without access to company filings or press releases beyond the RSS feed provided, the specific catalyst remains unclear.

APURR

Aperture AC

$0.17−$0.05

-22.5%

NASDAQ

No news headlines were found in the last 48 hours for APURR, so the 22.55% single-day drop likely reflects either a delayed market reaction to an untracked event, technical selling, or broader sector pressure on micro-cap stocks.

The absence of any recent news headlines makes it impossible to pinpoint a specific catalyst for the decline. Aperture AC is trading at $0.17, suggesting a micro-cap or penny stock classification where liquidity is typically thin and price swings can be amplified by modest volume shifts. For stocks in this category, declines of this magnitude can stem from several sources: delayed reporting of earnings misses or guidance cuts, insider selling or dilution announcements that took time to propagate, sector-wide rotation out of speculative positions, or technical breakdown of support levels that triggers algorithmic selling. Without access to company filings, insider transactions, or social media chatter that might have circulated before official news picked it up, we cannot determine which factor drove this particular move.

YSXT

YSX Tech. Co., LtdIndustrials

$1.01−$0.29

-22.3%

NASDAQ · Mkt cap $35 M

YSXT fell 22.31% on July 7, 2026, but no news headlines from the prior 48 hours are available to explain the move, making the precise catalyst unclear.

The absence of recent news headlines makes it difficult to pinpoint the exact driver of YSXT's sharp 22.31% decline. For a micro-cap or small-cap stock trading near $1.01, common catalysts include earnings misses or guidance cuts, insider selling or lock-up expirations, sector weakness, dilutive financing announcements, or broad market selloffs in growth or speculative equities. The stock's rank as the 21st biggest loser suggests it underperformed even the broader market decline on this date. Without access to company-specific announcements, regulatory filings, or industry news from the relevant timeframe, the move cannot be confidently attributed to any particular event. The timing and magnitude suggest a material negative development rather than routine volatility.

MIDD

The Middleby CorporationIndustrials

$139.26−$39.94

-22.3%

NASDAQ · Mkt cap $5.1 B

Middleby completed a spinoff of its Food Processing division (now Midera Food Processing) on July 6-7, 2026, which likely triggered a sharp 22% selloff as investors repriced the leaner parent company and digested the separation mechanics.

The headlines confirm that Middleby completed the spinoff of its Food Processing business into a standalone public company, Midera Food Processing, which began trading independently on July 7. Spinoffs often trigger sharp single-day moves due to several structural factors: forced selling by index funds and funds with mandate constraints, uncertainty about the newly separated parent's valuation without a major business segment, portfolio rebalancing, and the mechanical effect of shareholders receiving shares in two companies instead of one. The 22% drop is substantial but not atypical for a large spinoff announcement trading day, especially if the market reprices the remaining Middleby as less diversified or if there are redemption flows. The news that Midera is positioned as a "pure-play food processing technology platform" with 30+ brands suggests Middleby retained its other businesses, but investors may be uncertain about the parent's growth profile or margins post-separation.

CCHH

CCH Holdings Ltd Ordinary SharesConsumer Cyclical

$0.35−$0.10

-22.2%

NASDAQ · Mkt cap $4.3 M

CCHH dropped 22% today despite announcing a $50 million data center maintenance services agreement in Malaysia, suggesting market skepticism about either the deal's credibility, execution risk, or fundamental doubts about the company's pivot strategy.

The company announced a landmark $50 million maintenance services contract for data center infrastructure in Malaysia, framed as complementing its core restaurant franchise business. Normally such a contract would be positive news, yet the stock fell sharply, ranking among the day's biggest losers. This disconnect suggests several possibilities. First, investors may doubt the deal's substance or enforceability given CCHH's limited track record in data center services. Second, the market may view the pivot into infrastructure maintenance as a sign of weakness in the core restaurant business, interpreting diversification as a red flag rather than growth. Third, there could be concern about execution risk or financing of a $50 million commitment. Finally, the announcement timing or terms may contain language revealing unfavorable conditions not immediately apparent in the headline. Without additional detail on deal terms, payment milestones, or updated financial guidance, the precise cause remains unclear.

CWD

CaliberCos Inc.Financial Services

$0.82−$0.23

-21.9%

NASDAQ · Mkt cap $4.6 M

No news headlines were found in the last 48 hours for CWD, making it impossible to identify a specific catalyst for the 21.90% single-day drop.

CaliberCos Inc. experienced a sharp single-day decline of nearly 22% with zero identifiable news in the most recent 48-hour period. This absence of headlines does not rule out real catalysts; rather, it suggests either the triggering event occurred before the 48-hour window, arrived through a channel not captured by Yahoo Finance RSS feeds, or the move reflects delayed market reaction to older information or broader sector pressure. For micro-cap or thinly-traded NASDAQ stocks like CWD, price volatility can also be amplified by thin order books, forced selling from option expiration, or shifts in sentiment on social platforms. Without access to company filings, insider activity, technical levels, or related sector news, the precise driver remains speculative.

RBNE

Robin Energy Ltd.Energy

$0.52−$0.14

-21.4%

NASDAQ · Mkt cap $1.5 M

Robin Energy announced a reverse stock split effective July 9, 2026, which typically signals financial distress and triggers sell-offs as investors fear dilution and reduced liquidity despite the mechanical price adjustment.

The company announced a reverse stock split to take effect two days after the trading date. Reverse stock splits are commonly used by struggling companies to maintain minimum listing standards or improve optics, but markets typically react negatively because they signal underlying financial weakness rather than create fundamental value. Investors often interpret such moves as a precursor to further dilution, potential delisting concerns, or management's inability to grow the business organically. The headline confirms the announcement but does not specify the split ratio or stated rationale, limiting deeper analysis. The 21.36% single-day drop aligns with typical market skepticism toward reverse splits, even though the price will mechanically adjust post-split. For a maritime transport company like Robin Energy, broader sector headwinds or operational challenges may also contribute to the market's negative sentiment.

RKLX

Daily Target 2X Long RKLB ETF

$29.23−$7.72

-20.9%

NASDAQ

No news headlines were found in the last 48 hours, but RKLX is a 2X leveraged long ETF tracking Rocket Lab (RKLB), so a sharp decline likely reflects a significant drop in the underlying stock or broader market weakness amplified by the fund's leverage structure.

The absence of recent news headlines makes it impossible to identify a specific company-level catalyst. However, RKLX is a daily target 2X leveraged long ETF, which means its price movement is mechanically amplified relative to its underlying asset, Rocket Lab (RKLB). A 20.89% decline in RKLX would correspond roughly to a 10-11% decline in RKLB itself, assuming normal leverage tracking. This could result from several categories of events: adverse news about Rocket Lab's operations, contracts, or guidance; broader aerospace or defense sector weakness; overall market decline; or technical/liquidity factors specific to the ETF. Without headlines or knowledge of RKLB's movement today, the specific cause remains unknown, though leveraged equity ETFs are also sensitive to volatility and time decay in sideways or declining markets.

RDGT

Ridgetech, Inc.Healthcare

$1.33−$0.35

-20.8%

NASDAQ · Mkt cap $2.9 M

RDGT dropped 20.83% on July 7, 2026, but no news headlines were available in the prior 48 hours, making the specific trigger unclear and suggesting either a delayed announcement, technical breakdown, or market-specific catalyst not yet reflected in major feeds.

No recent news headlines were found to explain the sharp 20.83% decline in RDGT. This absence of public catalyst documentation is notable given the stock's substantial one-day loss and rank among the day's largest losers. The move could reflect several common scenarios: a negative earnings or revenue report released outside standard trading hours or without immediate RSS distribution, an executive departure or insider transaction, sector rotation pressure if RDGT operates in a cyclical industry, a delisting warning or reverse-split announcement, or technical selling triggered by a broken support level. Without access to company filings, press releases, or broader market context, attributing the move to any single cause would be speculative. The lack of headline coverage within 48 hours of a 20% drop is itself unusual and warrants investigation of company-specific filings or trading halts.

LCDL

GraniteShares 2x Long LCID Daily ETF

$0.71−$0.18

-20.6%

NASDAQ

No news headlines were published in the last 48 hours, but LCDL is a 2x leveraged long ETF tracking Lucid Motors, so a sharp decline likely reflects a significant drop in the underlying LCID stock driven by company-specific or broader EV sector weakness.

Zero headlines appear in the last 48 hours, which prevents attribution to a specific catalyst such as earnings, guidance, or news events. However, LCDL's structure as a daily leveraged 2x long ETF means its movements are directly amplified from the underlying Lucid Motors stock. A 20.59% decline in LCDL implies roughly a 10% or greater decline in LCID itself over the same period. This type of move in a speculative EV stock typically stems from operational updates, production concerns, cash burn reports, management changes, or broader sector selloffs in electric vehicles. Without explicit headlines, the cause remains in the inference category, but the mechanism through which LCDL moved is clear given its leverage structure.

LHAI

Linkhome Holdings Inc.Real Estate

$1.29−$0.32

-19.9%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours, so the 19.88% drop cannot be attributed to any publicly reported event; the cause remains unclear without additional context.

Linkhome Holdings experienced a significant single-day decline with no corresponding news coverage detected in the provided sources. When a stock of this size drops nearly 20% without accompanying headlines, several categories of catalyst are possible. The move could reflect delayed market reaction to an untracked announcement, technical selling in a lower-volume security, a sector-wide downturn not captured in company-specific news, short covering or liquidation, or negative commentary in channels outside the RSS feed sampled. Without earnings data, guidance changes, regulatory action, or other company-specific events visible in the headlines, attributing causation is speculative. Linkhome's position as the 29th biggest loser suggests material conviction behind the move, making it unlikely to be purely mechanical or noise-driven, yet the absence of news leaves the specific driver undetermined.

T1 Energy IncIndustrials

$6.95−$1.70

-19.6%

NYSE · Mkt cap $1.3 B

T1 Energy Inc fell 19.61% on July 7, 2026, with no news headlines reported in the last 48 hours, making the specific catalyst unclear; the decline likely reflects either a delayed market reaction to unreported company developments, sector weakness, or technical selling.

No recent news headlines are available to explain this significant 19.61% decline. Without concrete information about earnings misses, guidance cuts, regulatory setbacks, or other company-specific events, the cause remains speculative. For a smaller-cap energy company like T1 Energy, a drop of this magnitude could reflect several plausible but unconfirmed scenarios: (1) a delayed market reaction to an after-hours announcement or filing not yet picked up by major news feeds, (2) negative sector rotation out of energy or renewable energy plays, (3) technical breakdown following a period of strength, or (4) a private development adverse to the company that has not yet been publicly disclosed. Without access to intraday news wires, SEC filings, or conference calls, differentiating among these possibilities is not possible based on the available evidence.

SVAC

Spring Valley Acquisition Corp. III Class A Ordinary SharesFinancial Services

$8.25−$2.01

-19.6%

NASDAQ · Mkt cap $337 M

Spring Valley Acquisition Corp. III shareholders approved a business combination with General Fusion on July 6, which will result in the combined company trading under a new ticker (GFUZ), causing SVAC holders to face dilution and transition uncertainty.

The headline from July 6, 2026 confirms that SVAC shareholders approved the proposed merger with General Fusion, a private fusion company. This is a material corporate event for a SPAC. Upon completion of such a merger, SVAC shares are typically exchanged for shares of the new publicly traded entity (expected to trade as GFUZ on Nasdaq). The 19.59% drop likely reflects investor reaction to the deal terms, uncertainty about the combined entity's valuation, or pre-deal unwinding as investors liquidate SPAC positions ahead of the merger close. SPAC mergers are often met with selling pressure if market participants view the target company's valuation as rich relative to near-term earnings power or if there are concerns about execution risk in the fusion technology sector, which remains commercially unproven at scale.

LINT

Direxion Daily INTC Bull 2X ETF

$156.77−$37.64

-19.4%

NASDAQ

No news headlines available in the last 48 hours, but LINT is a 2X leveraged bull ETF on Intel, so a sharp decline in Intel's stock price would mechanically amplify the loss to roughly double that move.

The absence of any news headlines in the provided 48-hour window means we cannot identify a specific catalyst from public announcements. However, LINT's structure as a Direxion Daily 2X leveraged bull ETF on Intel (INTC) is critical context. This fund is designed to deliver approximately twice the daily return of its underlying index. If Intel shares fell roughly 9-10% on July 7, a 19% drop in LINT would be consistent with the leverage multiplier. The actual cause would therefore be whatever drove Intel lower that day—potentially earnings disappointment, analyst downgrades, sector weakness in semiconductors, geopolitical concerns affecting chip demand, or technical selling. Without specific Intel news in the headlines provided, we cannot determine which of these scenarios occurred, only that Intel weakness almost certainly triggered LINT's amplified decline.

TERG

Leverage Shares 2X Long TER Daily ETF

$37.65−$8.74

-18.8%

NASDAQ

No news headlines were found in the last 48 hours, but TERG is a 2X leveraged ETF tracking TER, so a sharp single-day drop likely reflects a significant decline in the underlying TER stock or a broader market selloff in that sector.

The absence of recent news headlines means we cannot point to a specific corporate event, earnings release, regulatory action, or market announcement. However, TERG's structure as a 2X daily leverage ETF is material to interpreting an 18.84% single-day loss. Leveraged ETFs amplify the daily moves of their underlying asset; a roughly 9-10% drop in TER stock would produce approximately this magnitude of loss in TERG. The most likely causes fall into two categories: either TER itself experienced a significant negative catalyst such as earnings disappointment, guidance reduction, sector headwinds, or a major contract loss, or broader market volatility affected the sector. Without headlines, we cannot distinguish between these scenarios or rule out technical factors such as rebalancing effects or liquidity events in the leveraged product itself.

IREG

Leverage Shares 2x Long IREN Daily ETF

$9.52−$2.17

-18.6%

NASDAQ

No news headlines were found in the last 48 hours, but the 18.56% decline is almost certainly due to a sharp drop in the underlying IREN stock, which this leveraged 2x ETF amplifies daily.

IREG is a 2x leveraged long daily ETF tracking IREN, meaning it is designed to deliver twice the daily return (positive or negative) of its underlying asset. With no news disclosed in the recent 48-hour window, the substantial single-day loss most likely reflects a significant decline in IREN itself, amplified by the 2x leverage structure. Leveraged ETFs are sensitive to intraday volatility and underlying price movements; a roughly 9% drop in IREN would translate to approximately the observed 18% loss in IREG. Without headlines explaining an IREN-specific catalyst, the underlying decline could stem from sector headwinds, technical selling, broader market weakness on the snapshot date, or undisclosed company-specific news not yet reflected in Yahoo Finance's RSS feed.

IRE

Defiance Daily Target 2X Long IREN ETF

$12.20−$2.78

-18.6%

AMEX

No news headlines were found in the last 48 hours, but the 18.56% decline in this 2X leveraged ETF is most likely driven by a sharp drop in its underlying stock or index on elevated market volatility.

IRE is a daily target 2X long leveraged ETF tracking IREN, which amplifies both gains and losses by approximately two times. Without any news headlines provided from the last 48 hours, we cannot identify a specific company-level catalyst. However, leveraged ETFs are highly sensitive to underlying asset price movements and market volatility. The 18.56% decline suggests the underlying security or index fell significantly—likely in the 8 to 10 percent range on a single day. This magnitude of move in a leveraged product typically reflects either broad market weakness, sector rotation, or a sharp intraday decline in the underlying name itself. Leveraged ETFs also experience daily rebalancing decay over time, which compounds losses during volatile periods, though a one-day move of this size is primarily driven by the underlying asset rather than decay mechanics alone.

RAY

Raytech Holding LimitedConsumer Defensive

$2.64−$0.60

-18.5%

NASDAQ · Mkt cap $16 M

No news headlines were found in the last 48 hours for RAY, so the 18.52% drop cannot be directly attributed to a specific announced event; the decline likely reflects either delayed disclosure of company news, technical selling, or broader sector pressure.

The absence of any recent news headlines is notable given RAY's ranking as the 36th biggest loser on the day. This suggests the catalyst either has not yet been widely reported by major financial media, occurred before the 48-hour window, or is unrelated to company-specific fundamentals. For small-cap or lower-liquidity stocks like those trading on NASDAQ at this price level, steep single-day declines can result from several causes: executive departures or insider selling not yet formally disclosed, deterioration in guidance expectations circulated informally, technical breakdown of support levels triggering algorithmic selling, sector-wide weakness affecting small-cap holdings, or delayed regulatory findings. Without corroborating headlines or structural insight into RAY's business, debt profile, or market positioning, the specific driver remains opaque.

ONTX

Onconova Therapeutics, Inc.Financial Services

$17.86−$4.06

-18.5%

GMEX

GMEX ROBOTICS CORPORATION Class ATechnology

$2.60−$0.59

-18.5%

NASDAQ · Mkt cap $1.0 M

GMEX announced a Letter of Intent to acquire a California robotics and AI company on July 6, but the stock fell 18.5% the next day, suggesting investor skepticism about deal terms, dilution concerns, or broader market/sentiment headwinds rather than enthusiasm for the transaction.

On July 6, GMEX disclosed a Letter of Intent to acquire an equity stake in a California-based robotics and industrial AI firm, positioning the deal as strategically important for eliminating wireless bottlenecks and enabling higher-margin software subscriptions. However, the stock dropped sharply the following trading day, which is counterintuitive if the market viewed this as unambiguously positive. Possible explanations include concern over acquisition price or dilution to existing shareholders, skepticism about execution risk or synergy claims, lack of detail on deal size and terms in the headline, or macroeconomic or sector-specific headwinds affecting robotics stocks broadly. Without additional reporting on deal valuation, financing structure, or management guidance, it is difficult to isolate whether the decline reflects rational repricing of the deal or other factors. The headline itself reads as promotional and does not provide financial details that would allow investors to assess fair value impact.

JEM

707 Cayman Holdings Limited Ordinary SharesConsumer Cyclical

$1.35−$0.30

-18.2%

NASDAQ · Mkt cap $2.8 M

No news was reported in the last 48 hours for JEM, so the 18% drop today likely stems from technical selling, market-wide weakness, or unannounced company developments not yet reflected in public headlines.

JEM experienced a sharp single-day decline of 18.18% on July 7, 2026, ranking among the day's biggest losers. However, no news headlines were available in the prior 48 hours to explain the move directly. For a thinly traded offshore holding company like 707 Cayman Holdings Limited, price swings of this magnitude can result from several sources: technical or momentum-driven selling by algorithmic or retail traders, broader market deterioration in a given sector or cap range, illiquidity amplifying modest sell pressure, or company-specific information that has not yet been picked up by mainstream financial news feeds. Without additional context on market conditions that day or company-specific catalysts, we cannot definitively isolate the cause.

RIVN

Rivian Automotive, Inc.Consumer Cyclical

$16.49−$3.65

-18.1%

NASDAQ · Mkt cap $23 B

Rivian announced a $1.5 billion secondary offering of 75 million shares, which triggered an 18% sell-off despite a positive Q2 revenue preview, as investors reacted negatively to the shareholder dilution.

The headlines establish a clear and consistent narrative across multiple sources. Rivian disclosed plans to sell 75 million shares to raise approximately $1.5 billion in capital. This is a classic equity dilution event that markets typically punish, as it increases the share count and reduces earnings per share for existing shareholders. The timing is notable because the stock had recently rallied 19%, and the company capitalized on that momentum to sell shares at a higher price—a deliberate tactical move. While the company simultaneously provided strong Q2 revenue guidance, that positive signal was entirely overshadowed by the dilution announcement. Investors prioritized the near-term shareholder value destruction from dilution over longer-term growth implications of the cash raise. The sell-off magnitude of 18% reflects the market's assessment of the dilution's negative impact, despite no apparent adverse developments in the underlying business fundamentals.

SDOT

Sadot Group Inc.Consumer Defensive

$40.00−$8.79

-18.0%

NASDAQ · Mkt cap $11 M

No news headlines were available in the last 48 hours, so the 18% drop cannot be attributed to a specific announced catalyst. The decline likely stems from technical selling, broader market conditions, or unannounced corporate developments.

The absence of recent news makes direct attribution impossible. An 18% single-day loss in a stock typically reflects either a material corporate announcement (earnings miss, guidance slash, insider departure, regulatory action), a technical breakdown following accumulated weakness, or sector-wide pressure. Without headlines to anchor the analysis, the most likely categories are delayed negative reporting not yet syndicated to Yahoo Finance, a pre-market or after-hours announcement, accumulating short selling pressure, or broader market stress affecting micro-cap securities disproportionately. Sadot Group is not a household name, so retail awareness of news may lag distribution channels.

RCAX

Daily Target 2X Long RCAT ETF

$4.48−$0.93

-17.2%

NASDAQ

No news headlines were found in the past 48 hours, but RCAX is a 2X leveraged long ETF tracking RCAT, so a decline in the underlying index would be amplified roughly twice over, making a ~17% drop plausible if RCAT fell approximately 8-9%.

RCAX is a daily target 2X long leveraged ETF, meaning it is designed to deliver twice the daily return of its underlying index RCAT. The absence of any breaking news in the last 48 hours suggests the decline is most likely attributable to a downturn in the underlying RCAT index itself rather than fund-specific issues. With leveraged ETFs, downside moves are magnified, so a moderate decline in RCAT would translate into a roughly doubled loss for RCAX holders. Possible drivers for RCAT weakness could include broad market selloffs, sector-specific headwinds affecting the holdings within RCAT, or profit-taking after a prior rally. Without access to RCAT performance data or broader market context for July 7, 2026, the specific catalyst remains unclear, but the mechanical leverage structure fully explains why RCAX moved proportionally harder than its underlying index.

BEG

Leverage Shares 2x Long BE Daily ETF

$64.93−$13.39

-17.1%

NASDAQ

No news headlines were found in the last 48 hours, so the 17.10% drop is likely attributable to a sharp decline in the underlying Blockchain ETF (BE) that this 2x leveraged fund tracks, amplified by the fund's daily reset mechanism.

BEG is a 2x leveraged daily ETF tracking the Blockchain ETF (BE). With no recent news available to explain the move, the decline almost certainly stems from weakness in the underlying blockchain and cryptocurrency assets that comprise BE. Leveraged ETFs amplify daily moves by 2x, so a roughly 8.5% drop in BE on the day would translate to approximately the 17.10% loss observed in BEG. Blockchain and crypto assets are highly sensitive to macroeconomic sentiment, regulatory concerns, technical chart breaks, and intraday momentum shifts. Without specific headlines, the trigger could be broad market volatility, sector rotation, liquidations, or negative sentiment in digital asset markets. The daily reset mechanism of leveraged ETFs also means performance decay can compound losses over multiple down days.

ZGM

Zenta Group Company LimitedIndustrials

$1.65−$0.34

-17.1%

NASDAQ · Mkt cap $35 M

No news headlines were found in the last 48 hours to explain ZGM's 17% drop on July 7, 2026. The cause remains unclear without additional information about company announcements, market conditions, or sector events.

The absence of any news in the Yahoo Finance RSS feed over the past two days makes it difficult to pinpoint a specific catalyst for ZGM's sharp 17% decline. For a micro-cap stock trading near $1.65, typical drivers of large single-day moves include delayed earnings releases or guidance warnings, sector-wide selloffs affecting small-cap technology or biotech plays, changes in short-seller positions or short-squeeze unwinding, liquidity events related to index rebalancing or fund redemptions, or broader market stress. Without headline evidence, it is reasonable to consider whether the stock experienced a technical breakdown below a support level, faced sudden insider selling or dilution announcements posted outside the RSS feed window, or was caught in a broader penny-stock or micro-cap rotation out of riskier assets.

TRNR

Interactive Strength Inc.Consumer Cyclical

$3.52−$0.71

-16.8%

NASDAQ · Mkt cap $4.2 M

Interactive Strength announced a major STEPR acquisition and raised 2026 pro forma revenue guidance to over $50m on July 7, yet the stock fell 16.78%, suggesting investor skepticism over deal valuation, dilution concerns, or execution risk despite the bullish strategic rationale.

The headlines reveal a seemingly positive catalyst: TRNR signed a definitive agreement to acquire STEPR, a profitable category leader in connected stair climbing expected to generate $15m+ revenue in 2026. The combined entity is guided to over $50m pro forma revenue. However, the stock's sharp 16.78% decline on the same day indicates the market is pricing in material headwinds. Likely concerns include: the transaction is performance-linked (suggesting earnout contingencies that may not materialize), potential dilution from equity financing or debt burden to fund the deal, skepticism about integrating a new acquisition, or valuation concerns about whether STEPR's growth justifies the purchase price. The headlines emphasize TRNR's bullishness but do not disclose the deal value, financing structure, or shareholder dilution, leaving investors to speculate on economics.

NBIG

Leverage Shares 2x Long NBIS Daily ETF

$18.72−$3.75

-16.7%

NASDAQ

No news headlines were found in the last 48 hours, but NBIG is a 2x leveraged long ETF tracking NBIS, so a sharp decline likely reflects a significant drop in the underlying index or broad market weakness that is amplified by the leverage structure.

The absence of company-specific or market-moving news in the provided headlines means the cause cannot be directly attributed to a named catalyst. However, NBIG's structural nature as a 2x daily leverage ETF is directly relevant here. Leveraged ETFs amplify the daily percentage moves of their underlying asset by a fixed multiple, so a 16.69% loss in NBIG would be consistent with approximately an 8-9% decline in the underlying NBIS index on this date. This kind of move typically occurs during broad market selloffs, sector rotations, or significant drops in the specific securities held by NBIS. Without news or market data for July 7, 2026, the most likely categories are general market weakness, sector-specific decline in technology or growth stocks, or a technical reversal after a sustained rally.

NBIL

GraniteShares 2x Long NBIS Daily ETF

$26.92−$5.35

-16.6%

NASDAQ

No headlines were reported in the last 48 hours, but NBIL is a 2x leveraged ETF that amplifies daily moves in its underlying index, so a sharp 16.58% decline likely reflects a significant drop in the underlying NBIS benchmark rather than company-specific news.

No news headlines are available to explain today's move directly. However, NBIL's structure as a 2x daily leveraged ETF is critical context. This fund is designed to deliver twice the daily return of its underlying benchmark, which means it amplifies both gains and losses. A 16.58% decline in NBIL would imply approximately an 8.3% decline in the underlying NBIS index or benchmark on the same day. Since no specific news headline is provided, the move likely stems from broad market volatility, sector rotation, or an event affecting the underlying index constituents. Without visibility into what NBIS tracks or what happened in that sector or market on July 7, 2026, we cannot pinpoint the exact catalyst, but leveraged ETFs are highly sensitive to daily market swings regardless of company fundamentals.

JTAI

Jet.AI Inc.Technology

$5.69−$1.11

-16.3%

NASDAQ · Mkt cap $2.4 M

Jet.AI stock fell 16.32% the day after shareholders approved a proposed transaction with flyExclusive, likely reflecting investor concern about deal terms, dilution, or integration risks despite the approval milestone.

The headline confirms that Jet.AI stockholders approved a proposed flyExclusive transaction on July 6, 2026. The sharp 16% decline on July 7 suggests the market reacted negatively to either the deal structure itself or the details disclosed during the shareholder vote process. Common reasons for post-approval selloffs include: unfavorable exchange ratios or consideration terms that became clear only at the shareholder meeting, concerns about the combined entity's ability to execute, competitive or market headwinds in the GPU infrastructure and AI cloud services space, or broader sector weakness. The news release provided is truncated and does not detail the transaction structure, so we cannot definitively identify which specific aspect triggered the sell-off. The approval itself is typically a positive catalyst, making the 16% decline unusual unless the market disagreed with the deal's strategic or financial terms.

FRMM

Forum Markets, IncorporatedTechnology

$5.70−$1.11

-16.3%

INLF

INLIF LimitedIndustrials

$5.35−$1.03

-16.1%

NASDAQ · Mkt cap $5.2 M

No news headlines were reported in the last 48 hours for INLIF Limited, so the 16.14% decline cannot be directly attributed to a specific disclosed event. The drop likely stems from technical selling, sector weakness, or undisclosed corporate developments.

The absence of news in the Yahoo Finance RSS feed over the past 48 hours means we cannot point to an earnings surprise, regulatory action, guidance change, or announced transaction as the cause of this sharp sell-off. For a microcap stock like INLIF trading at $5.35, daily moves of this magnitude can occur from several sources: profit-taking after a prior run, sector or broader market weakness, liquidity events, or material non-public information about to be disclosed. Without access to pre-market filings, short seller reports, or social media catalysts, we are limited to noting that the timing of the decline and absence of concurrent news suggests either a delayed market reaction to an earlier event or a catalyst not yet picked up by major news aggregators.